TY - JOUR T1 - High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients JF - Life Science Alliance JO - Life Sci. Alliance DO - 10.26508/lsa.202001009 VL - 4 IS - 9 SP - e202001009 AU - María Luisa Rodríguez de la Concepción AU - Erola Ainsua-Enrich AU - Esteban Reynaga AU - Carlos Ávila-Nieto AU - Jose Ramón Santos AU - Silvia Roure AU - Lourdes Mateu AU - Roger Paredes AU - Jordi Puig AU - Juan Manuel Jimenez AU - Nuria Izquierdo-Useros AU - Bonaventura Clotet AU - María Luisa Pedro-Botet AU - Jorge Carrillo Y1 - 2021/09/01 UR - https://www.life-science-alliance.org/content/4/9/e202001009.abstract N2 - The use of high-dose of intravenous immunoglobulins (IVIGs) as immunomodulators for the treatment of COVID-19–affected individuals has shown promising results. IVIG reduced inflammation in these patients, who progressively restored respiratory function. However, little is known about how they may modulate immune responses in COVID-19 individuals. Here, we have analyzed the levels of 41 inflammatory biomarkers in plasma samples obtained at day 0 (pretreatment initiation), 3, 7, and 14 from five hospitalized COVID-19 patients treated with a 5-d course of 400 mg/kg/d of IVIG. The plasmatic levels of several cytokines (Tumor Necrosis Factor, IL-10, IL-5, and IL-7), chemokines (macrophage inflammatory protein-1α), growth/tissue repairing factors (hepatic growth factor), complement activation (C5a), and intestinal damage such as Fatty acid–binding protein 2 and LPS-binding protein showed a progressive decreasing trend during the next 2 wk after treatment initiation. This trend was not observed in IVIG-untreated COVID-19 patients. Thus, the administration of high-dose IVIG to hospitalized COVID-19 patients may improve their clinical evolution by modulating their hyperinflammatory and immunosuppressive status. ER -